Unlocking the mysteries of the human brain

The Sydney Brain Bank is helping researchers uncover the causes of neurodegenerative disease and build a future with better diagnosis, treatment and prevention.

Unlocking the mysteries of the human brain

July 1, 2026
The Sydney Brain Bank is helping researchers uncover the causes of neurodegenerative disease and build a future with better diagnosis, treatment and prevention.
Read Transcript

The challenge

Neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease and Motor Neurone Disease have a significant and growing impact in Australia. Dementia is now the leading cause of death in Australia and affects more than 400,000 people. With an ageing population, this number is expected to increase to more than 1 million by 2065, placing increasing pressure on the healthcare system, aged care services and families.1

While these conditions are influenced by a complex interplay of genetic, lifestyle and environmental factors, many questions remain about how environmental exposures affect brain health and contribute to disease.

Research has linked factors such as repetitive head injury, air pollution and other environmental toxins to changes in brain health. However, much remains unknown about the role these exposures may play in neurodegenerative disease.

The Sydney Brain Bank (SBB) at Neuroscience Research Australia (NeuRA) addresses the critical need for post-mortem brain and spinal cord tissue to advance scientific understanding of healthy ageing and neurodegenerative conditions, as well as the impact of environmental toxins on brain health and disease.

Highlights

In 2025, NeuRA researchers published a world-first study identifying per- and polyfluoroalkyl substances (PFAS), often referred to as "forever chemicals", in brain tissue collected through the SBB. The findings demonstrated that these environmental chemicals can cross the blood-brain barrier and accumulate in human brain tissue. The work attracted significant national attention and provided essential groundwork for future research into whether PFAS and other environmental toxins preferentially accumulate in diseases such as Motor Neurone Disease and Parkinson's Disease, both of which are thought to be impacted by environmental toxins.

The role of philanthropy

Hearts & Minds funding, as nominated by Caledonia, has been critical in sustaining the infrastructure of the SBB. This funding has helped the facility fulfil its mission of collecting, characterising, storing, and distributing high-quality human brain and spinal cord tissue for research, ensuring scientists have access to the resources needed to advance discoveries.

What this could unlock

The SBB is creating new opportunities to better understand the causes of neurodegenerative disease and the factors that influence brain health. Through this work, researchers hope to support earlier diagnosis, improved treatments and better outcomes for people affected by these devastating conditions.

1. Dementia Australia, Dementia facts and figures.

This project is supported by Hearts & Minds, as nominated by Core Fund Manager, Caledonia. For further information and updates, visit NeuRA. This content was last updated in July 2026.

The challenge

Neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease and Motor Neurone Disease have a significant and growing impact in Australia. Dementia is now the leading cause of death in Australia and affects more than 400,000 people. With an ageing population, this number is expected to increase to more than 1 million by 2065, placing increasing pressure on the healthcare system, aged care services and families.1

While these conditions are influenced by a complex interplay of genetic, lifestyle and environmental factors, many questions remain about how environmental exposures affect brain health and contribute to disease.

Research has linked factors such as repetitive head injury, air pollution and other environmental toxins to changes in brain health. However, much remains unknown about the role these exposures may play in neurodegenerative disease.

The Sydney Brain Bank (SBB) at Neuroscience Research Australia (NeuRA) addresses the critical need for post-mortem brain and spinal cord tissue to advance scientific understanding of healthy ageing and neurodegenerative conditions, as well as the impact of environmental toxins on brain health and disease.

Highlights

In 2025, NeuRA researchers published a world-first study identifying per- and polyfluoroalkyl substances (PFAS), often referred to as "forever chemicals", in brain tissue collected through the SBB. The findings demonstrated that these environmental chemicals can cross the blood-brain barrier and accumulate in human brain tissue. The work attracted significant national attention and provided essential groundwork for future research into whether PFAS and other environmental toxins preferentially accumulate in diseases such as Motor Neurone Disease and Parkinson's Disease, both of which are thought to be impacted by environmental toxins.

The role of philanthropy

Hearts & Minds funding, as nominated by Caledonia, has been critical in sustaining the infrastructure of the SBB. This funding has helped the facility fulfil its mission of collecting, characterising, storing, and distributing high-quality human brain and spinal cord tissue for research, ensuring scientists have access to the resources needed to advance discoveries.

What this could unlock

The SBB is creating new opportunities to better understand the causes of neurodegenerative disease and the factors that influence brain health. Through this work, researchers hope to support earlier diagnosis, improved treatments and better outcomes for people affected by these devastating conditions.

1. Dementia Australia, Dementia facts and figures.

This project is supported by Hearts & Minds, as nominated by Core Fund Manager, Caledonia. For further information and updates, visit NeuRA. This content was last updated in July 2026.

Disclaimer: This material has been prepared by Hearts & Minds, published on July 1, 2026. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
July 1, 2026

Understanding fatigue in young people with Charcot-Marie-Tooth disease

Developing a tool to improve understanding, research and care.

Read More
Pictured left to right: Professor Gina Ravenscroft (Perkins), Jasmine Chew, Sam Payne (CEO and Founder, Pink Elephants Support Network), and Shelby Mullin (Perkins).Pictured left to right: Professor Gina Ravenscroft (Perkins), Jasmine Chew, Sam Payne (CEO and Founder, Pink Elephants Support Network), and Shelby Mullin (Perkins).Pictured left to right: Professor Gina Ravenscroft (Perkins), Jasmine Chew, Sam Payne (CEO and Founder, Pink Elephants Support Network), and Shelby Mullin (Perkins).Pictured left to right: Professor Gina Ravenscroft (Perkins), Jasmine Chew, Sam Payne (CEO and Founder, Pink Elephants Support Network), and Shelby Mullin (Perkins).
July 1, 2026

Giving families living with rare diseases the answers they need

Supporting research to improve the diagnosis of rare genetic neuromuscular diseases and build the foundations for future treatments.

Read More
Picture: Dr Laura Grice, Lead Researcher Picture: Dr Laura Grice, Lead Researcher Picture: Dr Laura Grice, Lead Researcher Picture: Dr Laura Grice, Lead Researcher
July 1, 2026

Understanding spinal cord injury recovery

The world's first molecular map of spinal cord injury across time and injury levels

Read More
Picture: Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium Picture: Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium Picture: Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium Picture: Professor Lindy Jeffree, Neurosurgeon and Chair, Brain Cancer Australia National Consortium
July 1, 2026

Building the foundations for faster progress against brain cancer

Uniting researchers, clinicians and patients to accelerate research and improve patient care.

Read More
July 1, 2026

Accelerating CAR-T cell therapies for patients in need 

Bringing innovative cancer therapies closer to patients.

Read More
July 1, 2026

Supporting babies at high risk of cerebral palsy from the very beginning

Testing a family-centred early intervention program to improve outcomes for infants and support parents during the first critical months of life.

Read More
July 1, 2026

Making early cerebral palsy screening more accessible

Exploring new ways to identify babies at risk of cerebral palsy sooner and support better outcomes.

Read More
Picture: Professor Tracy Putoczki, Laboratory Head at WEHIPicture: Professor Tracy Putoczki, Laboratory Head at WEHIPicture: Professor Tracy Putoczki, Laboratory Head at WEHIPicture: Professor Tracy Putoczki, Laboratory Head at WEHI
July 1, 2026

Mapping the surface of pancreatic cancer cells

Identifying proteins on pancreatic cancer cells that could become new targets for developing future treatments.

Read More
Picture: Professor Jane Visvader and Professor Geoff Lindeman from the Breast Cancer Laboratory at WEHI Picture: Professor Jane Visvader and Professor Geoff Lindeman from the Breast Cancer Laboratory at WEHI Picture: Professor Jane Visvader and Professor Geoff Lindeman from the Breast Cancer Laboratory at WEHI Picture: Professor Jane Visvader and Professor Geoff Lindeman from the Breast Cancer Laboratory at WEHI
July 1, 2026

Understanding how breast cancer begins

Tracking the earliest changes in BRCA mutation carriers to help prevent cancer before it starts.

Read More
July 1, 2026

A new path forward for women living with period and pelvic pain

Uncovering the biology driving debilitating symptoms

Read More
Picture: Professor Daniel MacArthurPicture: Professor Daniel MacArthurPicture: Professor Daniel MacArthurPicture: Professor Daniel MacArthur
July 1, 2026

Closing the gap in rare disease diagnosis for Australian families

Building better genomic tools and more representative data to help families receive answers sooner.

Read More
PICTURE: A/Prof Rebecca Nisbet and her teamPICTURE: A/Prof Rebecca Nisbet and her teamPICTURE: A/Prof Rebecca Nisbet and her teamPICTURE: A/Prof Rebecca Nisbet and her team
July 1, 2026

Developing a new mRNA vaccine for Alzheimer’s disease

Using innovative technology to explore new possibilities for treatment and prevention.

Read More
Researchers are growing human “mini-brains” in the laboratory and introducing immune cells from people living with MS. Researchers are growing human “mini-brains” in the laboratory and introducing immune cells from people living with MS. Researchers are growing human “mini-brains” in the laboratory and introducing immune cells from people living with MS. Researchers are growing human “mini-brains” in the laboratory and introducing immune cells from people living with MS.
July 1, 2026

Unlocking new approaches for Multiple Sclerosis

Understanding why the brain fails to repair itself and exploring new treatment possibilities.

Read More

Helping emergency doctors make faster decisions with AI

Using Australian-developed artificial intelligence to improve emergency care.

Read More
July 1, 2026

Protecting vulnerable children, when it matters most

How the Safer Kids Project is helping identify and protect children at risk in emergency care

Read More